Michael Amiri, MD
Neurology · Charlotte, NCNPI 1720161011
Payments from drug & device makers
Across 1,921 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Teva Pharmaceuticals USA, Inc.$2K
- UCB, Inc.$2K
- Eisai Inc.$2K
- AbbVie$1K
- Sunovion Pharmaceuticals Inc.$1K
- plus $20K from 54 others
What the payments were for
- Consulting fees$80%
- Speaking & faculty fees$5442%
- Travel & lodging$6162%
- Food & beverage$29,20494%
- Education$5702%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,942 in reported general payments places this provider in the 75th percentile of 566 neurology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BriviactBrivaracetam | 163 | $242,651 |
| VumerityDiroximel Fumarate | 17 | $144,319 |
| Austedo XrDeutetrabenazine | 15 | $97,929 |
| IngrezzaValbenazine Tosylate | 11 | $93,881 |
| FycompaPerampanel | 69 | $90,280 |
| Nurtec OdtRimegepant Sulfate | 56 | $88,774 |
| EpidiolexCannabidiol (Cbd) | 17 | $79,659 |
| XcopriCenobamate | 39 | $43,173 |
| QuliptaAtogepant | 35 | $37,177 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 45 | $36,582 |
| AptiomEslicarbazepine Acetate | 22 | $34,810 |
| NuedextaDextromethorphan Hbr/Quinidine | 18 | $27,379 |
| UbrelvyUbrogepant | 20 | $22,221 |
| NayzilamMidazolam | 20 | $19,644 |
| Lacosamide | 160 | $17,465 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Nayzilam | $1,629 | $262,295183 claims |
| BiogenVumerity | $846 | $144,31917 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $2,117 | $97,92915 claims |
| PfizerNurtec Odt, Dilantin | $968 | $94,888102 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $580 | $93,88111 claims |
| Eisai Inc.Fycompa | $1,594 | $90,28069 claims |
| AbbVieQulipta, Ubrelvy | $1,429 | $59,39855 claims |
| SK Life Science, Inc.Xcopri | $815 | $43,17339 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $1,373 | $34,81022 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $285 | $27,37918 claims |
| Lilly USA, LLCOlanzapine | $987 | $1,87639 claims |
| Upsher-smith Laboratories LLCTopiramate | $146 | $1,409225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 566 neurology providers in North Carolina.
Other neurology in Charlotte
- Mohammad BolouriCharlotte$16.6M
- T RaoCharlotte$4M
- Donna GravesCharlotte$1.8M
- Jill ConwayCharlotte$1.6M
- Matthew CarraroCharlotte$1.5M
- Urvi DesaiCharlotte$937K
- Ardith CourtneyCharlotte$862K
- Sanjay IyerCharlotte$685K
- Megan DonnellyCharlotte$601K
- Kenneth AshkinCharlotte$525K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.